Diabetic macular edema management
-
Introduction on DME
00:00:00 -
Limitations of current standard of care in DME
00:03:54 -
Inflammation in DME
00:07:15 -
Treatment burden in DME
00:17:34 -
Comorbidities in DME
00:19:31 -
Ozurdex reimbursement criteria in DME
00:20:24 -
Ozurdex pivotal trials
00:21:03 -
Ozurdex safety profile
00:21:50 -
Early vs late switch
00:24:10 -
Belgian & Euretina DME guidelines
00:25:07 -
Summary of theoretical part
00:26:43
Role of inflammation in DME & Clinical cases
-
Introduction on DME
00:00:00 -
Limitations of current standard of care in DME
00:04:38 -
Inflammation in DME
00:10:15 -
Treatment burden in DME
00:15:29 -
Comorbidities in DME
00:22:56 -
Ozurdex reimbursement criteria in DME
00:26:51 -
Ozurdex pivotal trials
00:27:21 -
Ozurdex safety profile
00:28:10 -
Belgian & Euretina DME guidelines
00:29:58 -
Summary of theoretical part
00:33:40
Inflammation in DME: What can Ozurdex bring to you
-
Introduction
00:00:00 -
Limitations of current standard of care in DME
00:10 -
Inflammation in DME
00:02:00 -
Shall we stay or shall we switch
00:06:05 -
Ozurdex reimbursement criteria in DME
00:06:35 -
What is Ozurdex?
00:07:47 -
Ozurdex pivotal trials
00:09:04 -
RWE of Anti-Vegf and Ozurdex
00:11:45 -
Dr Fasolino’s experience with Ozurdex
00:12:44 -
Patient Case 1
00:14:09 -
Ozurdex and cataract surgery in DME
00:15:20 -
Patient Case 3
00:17:10 -
Take home message
00:18:31
Indications for Ozurdex treament
-
Introduction
00:00:00 -
Limitations of current standard of care in DME
00:07:29 -
Inflammation in DME
00:15:20 -
Corticosteroids in DME
00:25:30 -
Ozurdex reimbursement criteria in DME
00:26:04 -
Ozurdex pivotal trials
00:28:18 -
Advantages and limitations of current DME treatments
00:32:10 -
Ozurdex safety profile
00:38:46 -
Belgian & Euretina DME guidelines
00:40:56